Respironics to Webcast Fiscal 2007 Third Quarter Conference Call
12 Abril 2007 - 9:00AM
PR Newswire (US)
MURRYSVILLE, Pa., April 12 /PRNewswire-FirstCall/ -- Respironics,
Inc. (NASDAQ:RESP), a recognized resource in the medical device
market, announced today that it intends to release its third
quarter results for the period ending March 31, 2007 on Thursday,
April 26, 2007. In conjunction with this release and to review the
Company's results and business outlook, Respironics will host a
conference call that will be broadcast simultaneously live over the
Internet. Individuals wishing to participate on the Webcast, to be
held at 8:30 a.m. EST on Thursday, April 26, 2007, can access the
event at the Company's web site at http://www.respironics.com/.
Please allow extra time prior to the call to visit the site and
download the streaming media software required to listen to the
Internet broadcast. The online archive of the broadcast will be
available within 2 hours of the live call and will be available for
30 days. Respironics is a leading developer, manufacturer and
distributor of innovative products and programs that serve the
global sleep and respiratory markets. Focusing on emerging market
needs, the Company is committed to providing valued solutions to
help improve outcomes for patients, clinicians and healthcare
providers. Respironics markets its products in 131 countries and
employs over 4,900 associates worldwide. Further information can be
found on the Company's Web site: http://www.respironics.com/.
CAUTIONARY STATEMENT FOR PURPOSES OF THE "SAFE HARBOR" PROVISIONS
OF THE PRIVATE SECURITIES REFORM ACT OF 1995. This document
contains forward-looking statements, including statements relating
to, among other things, developments in the healthcare industry;
the success of the Company's marketing, sales, and promotion
programs; future sales, acceptance, and quality of the Company's
products and programs; the results of clinical trials; the timing
and success of new product introductions; new product development;
anticipated cost savings; FDA and other regulatory requirements,
enforcement actions, product recalls or related field actions;
future results from acquisitions and strategic investments; growth
rates in foreign markets; regulations and other factors affecting
operations and sales outside the United States; foreign currency
fluctuations; the effects of a major natural disaster, cyber-attack
or other catastrophic event that results in the destruction or
disruption of any critical business or information technology
systems; customer consolidation and concentration; increasing price
competition and other competitive factors in the manufacture,
distribution, and sale of products; interest rate fluctuations;
expiration of intellectual property rights; intellectual property
and related litigation; other litigation; future levels of earnings
and revenues; the number of equity awards granted to employees and
changes in the Company's stock price; and third party
reimbursement; all of which are subject to change. Actual results
may differ materially from those described in any forward-looking
statements. Additional information on potential factors that could
affect the Company's financial results are included in the reports
filed with the SEC, including the reports on Form 10-K, 10-Q and
8-K. DATASOURCE: Respironics, Inc. CONTACT: Dan Bevevino, Vice
President & CFO, +1-724-387-5235, or General, Joe Calabrese,
+1-212-827-3772, or Analyst, Julie Tu, +1-212-827-3776, all of
Financial Relations Board, for Respironics, Inc. Web site:
http://www.respironics.com/
Copyright
Respironics (NASDAQ:RESP)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Respironics (NASDAQ:RESP)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Respironics (MM) (NASDAQ): 0 recent articles
Más de Respironics (MM) Artículos de Noticias